EGFR and neoplasm: In line with a recent report [19] 20 minutes of treatment with 10μM of erlotinib potently suppressed tumor cell growth of the erlotinib sensitive cell lines HCC827 and PC9 (both carry EGFR exon 19 deletion mutations) as effectively as a continuous 72 hours exposure with 0.1μM.